EZ Cap™ EGFP mRNA (5-moUTP)

Référence R1016-1

Conditionnement : 1mg(1mg/mL)

Marque : APExBIO Technology

Demander plus d'informations

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

EZ Cap™ EGFP mRNA (5-moUTP)

Skip to the end of the images gallery
Skip to the beginning of the images gallery
Featured Products

Background

EZ Cap™ EGFP mRNA (5-moUTP) will express enhanced green fluorescent protein(EGFP)  once entering cells originally isolated from the jellyfish(Aequorea victoria). You can observe the green fluorescence at 509 nm. EGFP is usually used as a reporter for gene regulation and function study. It is applicable in assays for mRNA delivery, translation efficiency, cell viability and in vivo imaging etc.

EZ Cap™ EGFP mRNA (5-moUTP) is provided at a concentration of ~1 mg/ml with Cap1 structure. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of 5-moUTP and poly(A) tail suppress RNA-mediated innate immune activation and increase the stability and lifetime of the mRNA in vitro and in vivo. Poly(A) tail also plays an important role in enhancing the efficiency of translation initiation.

Product Citation

  • 1. Xueying Tang, et al. "Durable protective efficiency provide by mRNA vaccines require robust immune memory to antigens and weak immune memory to lipid nanoparticles." Mater Today Bio. 2024 Feb 9:25:100988. PMID: 38379935
  • 2. Yixuan Huang, Jiacai Wu, et al. "Quaternization drives spleen-to-lung tropism conversion for mRNA-loaded lipid-like nanoassemblies." Theranostics. 2024 Jan 1;14(2):830-842. PMID: 38169552
  • 3. Mingzhu Gao, Maoping Tang, et al. "Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis." ACS Nano. 2023 Sep 26;17(18):17721-17739. PMID: 37669404
  • 4. Y. Huang, M. Yang, et al. "Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles." Materials Today Advances.
  • 5. Min Li, Yixuan Huang, et al. "A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice." Materials Horizons. PMID: 36468425

Quality Control

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
R1007-100ug
 100ug(1mg/mL) 
R1001-100ug
 100ug(1mg/mL)